Pharmacy

Pharmacy Question for the Week of March 2, 2020

Pharmacy Compliance Question of the Week

Question:

What is the MAT treatment?

Answer:

According to the white paper “Healthcare Strategies to Reduce the Harm of Opioids” prepared by the Healthcare Fraud Prevention Partnership: “MAT combines one of three Food and Drug Administration (FDA) approved medications (methadone, buprenorphine, and naltrexone) with behavioral therapy for preventing relapse and for maintenance treatment of OUD. Research demonstrates that MAT is a cost-effective method that is more effective at retaining patients in treatment and reducing opioid misuse than approaches such as tapering, detoxification, or abstinence, which are all associated with higher rates of relapse.”

CPT© copyright 2020 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.